Document Detail


Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
MedLine Citation:
PMID:  10848649     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This review examines the evidence for the development of adverse effects due to prolonged gastric acid suppression with proton pump inhibitors. Potential areas of concern regarding long-term proton pump inhibitor use have included: carcinoid formation; development of gastric adenocarcinoma (especially in patients with Helicobacter pylori infection); bacterial overgrowth; enteric infections; and malabsorption of fat, minerals, and vitamins. Prolonged proton pump inhibitor use may lead to enterochromaffin-like cell hyperplasia, but has not been demonstrated to increase the risk of carcinoid formation. Long-term proton pump inhibitor treatment has not been documented to hasten the development or the progression of atrophic gastritis to intestinal metaplasia and gastric cancer, although long-term studies are required to allow definitive conclusions. At present, we do not recommend that patients be tested routinely for H. pylori infection when using proton pump inhibitors for prolonged periods. Gastric bacterial overgrowth does increase with acid suppression, but important clinical sequelae, such a higher rate of gastric adenocarcinoma, have not been seen. The risk of enteric infection may increase with acid suppression, although this does not seem to be a common clinical problem with prolonged proton pump inhibitor use. The absorption of fats and minerals does not appear to be significantly impaired with chronic acid suppression. However, vitamin B12 concentration may be decreased when gastric acid is markedly suppressed for prolonged periods (e.g. Zolllinger-Ellison syndrome), and vitamin B12 levels should probably be assessed in patients taking high-dose proton pump inhibitors for many years. Thus, current evidence suggests that prolonged gastric acid suppression with proton pump inhibitors rarely, if ever, produces adverse events. Nevertheless, continued follow-up of patients taking proton pump inhibitors for extended periods will provide greater experience regarding the potential gastrointestinal adverse effects of long-term acid suppression.
Authors:
L Laine; D Ahnen; C McClain; E Solcia; J H Walsh
Related Documents :
17229219 - Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors.
2655299 - Reducing the risk of aspiration pneumonitis.
15711649 - Experimental acute lung injury. effects of methylprednisolone and lidocaine on histopat...
3826379 - Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity?
5037069 - The slowing of gastric emptying by four strong acids and three weak acids.
959759 - Relationships between gastric acid secretion and recurrent duodenal ulcer after selecti...
20594849 - Aryl boronic acid inhibition of synthetic melanin polymerization.
2398029 - High-performance liquid chromatographic analysis of alpha-keto acids produced from amin...
6412709 - A new class of lipoxygenase inhibitor. polyunsaturated fatty acids containing sulfur.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  14     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2000 Jun 
Date Detail:
Created Date:  2000-08-01     Completed Date:  2000-08-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  651-68     Citation Subset:  IM    
Affiliation:
University of Southern California School of Medicine, Los Angeles, California 90033, USA. llaine@usc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / chemically induced*
Anti-Ulcer Agents / administration & dosage,  adverse effects*
Carcinoid Tumor / chemically induced*
Gastric Acid / metabolism*
Helicobacter Infections / complications
Humans
Malabsorption Syndromes / chemically induced
Proton Pumps / antagonists & inhibitors*
Risk Factors
Stomach Diseases / chemically induced
Stomach Neoplasms / chemically induced*
Stomach Ulcer / drug therapy
Chemical
Reg. No./Substance:
0/Anti-Ulcer Agents; 0/Proton Pumps
Comments/Corrections
Comment In:
Aliment Pharmacol Ther. 2001 May;15(5):729-30   [PMID:  11328270 ]
Aliment Pharmacol Ther. 2000 Nov;14(11):1537-8   [PMID:  11069327 ]
Aliment Pharmacol Ther. 2001 Jul;15(7):1085-6   [PMID:  11421886 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of alpha1-adrenergic stimulation of Cl- secretion and signal transduction in exocrine glands ...
Next Document:  Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.